Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Commits To Major Expansion In Germany As Part Of Global ADC Push

€1bn Investment

Executive Summary

Daiichi Sankyo will expand its production site in Pfaffenhofen, Germany with new R&D capability for antibody-drug conjugates, spending €1bn. Behind the major new investment, the firm has recently filed for the approval of two ADCs in the US and is preparing global approval filings including in Europe and Asia.

You may also be interested in...



Dato-DXd Filing Lifts Mood For AstraZeneca Investors

AstraZeneca and Daiichi-Sankyo are targeting only non-squamous patients with their first Dato-DXd filing, but are still on course for a first-in-class approval by year end.

From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo

When George Nakayama was assigned to lead Daiichi Sankyo despite his atypical background, the firm was facing several crises, including a probe into the acquisition of Ranbaxy and a looming patent cliff. So, what made him decide to focus on ADCs while reshaping the entire company? 

Daiichi Sankyo’s Growth Plan Is Built On ADCs

The Japanese pharma has established itself as an early leader in antibody-drug conjugates (ADCs) for cancer. Global oncology business head Ken Keller talked to Scrip about the portfolio, pipeline and deals.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel